Incretin-based therapies, GLP-1 receptor (GLP-1R) agonists and DPP-4 inhibitors, enhance the glucose-dependent insulin secretion and optimize the management of glycemic control without hypoglycemia and weight gain [26]. This evidence concerns the gene INS and Hypoglycemia.